Successful treatment of Verona integron-encoded metallo-β-lactamase-producing<i>Klebsiella pneumoniae</i>infection using the combination of ceftazidime/avibactam and aztreonam

Bejarano, A Peláez; Moral, Raquel Sánchez-del; Pérez, O Montero; Martínez‐Marcos, Francisco Javier

doi:10.1136/ejhpharm-2021-002772

Cited by 3 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data from the National Healthcare Safety Network from 2015 to 2017 show that among P. aeruginosa isolates in ICU patients, 26.3% were resistant to carbapenems, 26.5% were resistant to extended-spectrum cephalosporins and 27.1% were resistant to fluoroquinolones, with 18.6% classified as MDR [ 71 ]. Increasing resistance has led clinicians to employ antimicrobial “cocktails” in the hopes of salvaging patients with MDR/XDR infections [ 72 , 73 ]. Verona integron-encoded metallo-β-lactamase-positive P. aeruginosa (VIM-PA) has emerged as one of the most resistant Gram-negative pathogens, along with carbapenem-resistant A. baumannii .…”

Section: Impact Of Gram-negative Antibiotic-resistant Pulmonary Infec...mentioning

confidence: 99%

The threat of multidrug-resistant/extensively drug-resistant Gram-negative respiratory infections: another pandemic

Reynolds

Burnham²,

Guillamet³

et al. 2022

Eur Respir Rev

View full text Add to dashboard Cite

Antibiotic resistance is recognised as a global threat to human health by national healthcare agencies, governments and medical societies, as well as the World Health Organization. Increasing resistance to available antimicrobial agents is of concern for bacterial, fungal, viral and parasitic pathogens. One of the greatest concerns is the continuing escalation of antimicrobial resistance among Gram-negative bacteria resulting in the endemic presence of multidrug-resistant (MDR) and extremely drug-resistant (XDR) pathogens. This concern is heightened by the identification of such MDR/XDR Gram-negative bacteria in water and food sources, as colonisers of the intestine and other locations in both hospitalised patients and individuals in the community, and as agents of all types of infections. Pneumonia and other types of respiratory infections are among the most common infections caused by MDR/XDR Gram-negative bacteria and are associated with high rates of mortality. Future concerns are already heightened due to emergence of resistance to all existing antimicrobial agents developed in the past decade to treat MDR/XDR Gram-negative bacteria and a scarcity of novel agents in the developmental pipeline. This clinical scenario increases the likelihood of a future pandemic caused by MDR/XDR Gram-negative bacteria.

show abstract

Section: Impact Of Gram-negative Antibiotic-resistant Pulmonary Infec...mentioning

confidence: 99%

The threat of multidrug-resistant/extensively drug-resistant Gram-negative respiratory infections: another pandemic

Reynolds

Burnham²,

Guillamet³

et al. 2022

Eur Respir Rev

View full text Add to dashboard Cite

show abstract

Evolving resistance landscape in gram‐negative pathogens: An update on β‐lactam and β‐lactam‐inhibitor treatment combinations for carbapenem‐resistant organisms

Koenig,

Kuti

2024

Pharmacotherapy

View full text Add to dashboard Cite

Antibiotic resistance has become a global threat as it is continuously growing due to the evolution of β‐lactamases diminishing the activity of classic β‐lactam (BL) antibiotics. Recent antibiotic discovery and development efforts have led to the availability of β‐lactamase inhibitors (BLIs) with activity against extended‐spectrum β‐lactamases as well as Klebsiella pneumoniae carbapenemase (KPC)‐producing carbapenem‐resistant organisms (CRO). Nevertheless, there is still a lack of drugs that target metallo‐β‐lactamases (MBL), which hydrolyze carbapenems efficiently, and oxacillinases (OXA) often present in carbapenem‐resistant Acinetobacter baumannii. This review aims to provide a snapshot of microbiology, pharmacology, and clinical data for currently available BL/BLI treatment options as well as agents in late stage development for CRO harboring various β‐lactamases including MBL and OXA‐enzymes.

show abstract

Rapid characterization of carbapenem-resistant Enterobacterales by multiplex lateral flow assay and detection of ceftazidime-avibactam-aztreonam synergy

Kalaivani,

Kali,

Surendran

et al. 2024

Indian Journal of Medical Microbiology

View full text Add to dashboard Cite

Successful treatment of Verona integron-encoded metallo-β-lactamase-producingKlebsiella pneumoniaeinfection using the combination of ceftazidime/avibactam and aztreonam

Cited by 3 publications

References 16 publications

The threat of multidrug-resistant/extensively drug-resistant Gram-negative respiratory infections: another pandemic

The threat of multidrug-resistant/extensively drug-resistant Gram-negative respiratory infections: another pandemic

Evolving resistance landscape in gram‐negative pathogens: An update on β‐lactam and β‐lactam‐inhibitor treatment combinations for carbapenem‐resistant organisms

Rapid characterization of carbapenem-resistant Enterobacterales by multiplex lateral flow assay and detection of ceftazidime-avibactam-aztreonam synergy

Contact Info

Product

Resources

About